AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15615749 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical induction of chorioretinal venous anastomosis
Number of subjects: 28
Study 15615749 — intervention group
Group type: COMPARATOR
Intervention: Control (no surgery)
Number of subjects: 28
Study 12453326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) 425 mg/m2 with low-dose folinic acid (FA) 20 mg/m2, administered as a rapid bolus intravenous injection for 5 days every 4-5 weeks
Number of subjects: 412
Study 12453326 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) with low-dose folinic acid (FA)
Number of subjects: 412
Study 10445530 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg/kg) administered intravenously over 15 min before consumption of 300 g minced beef and 150 ml water.
Number of subjects: 6
Study 7556858 — intervention group
Group type: COMPARATOR
Intervention: 600 mg ibuprofen preoperatively
Number of subjects: 619
Study 7556858 — intervention group
Group type: COMPARATOR
Intervention: Buffered 1% lidocaine
Number of subjects: 619
Study 7556858 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting times of 0, 3 and 10-20 min between injection and procedure
Number of subjects: 619
Study 7556858 — intervention group
Group type: COMPARATOR
Intervention: Slow injection of local anesthetic into one side of the cervix
Number of subjects: 619
Study 2300411 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular vaccine
Number of subjects: 201
Study 2300411 — intervention group
Group type: COMPARATOR
Intervention: Whole cell vaccine
Number of subjects: 201
Study 2300411 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of acellular vaccine
Number of subjects: 201
Study 383273 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 cycles of CVP (cyclophosphamide + vincristine + prednisolone)
Number of subjects: 55
Study 383273 — intervention group
Group type: COMPARATOR
Intervention: No further therapy
Number of subjects: 55
Study 383273 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 55
Study 383273 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 55
Study 30465917 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate supplementation (1500 mg Ca/d)
Number of subjects: 290
Study 30465917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study 28107846 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing patterns during the active phase of the first stage of labor
Number of subjects: 140
Study 28107846 — intervention group
Group type: COMPARATOR
Intervention: Routine care service (Control)
Number of subjects: 140
Study 25529474 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofinity Multifocal D(®)
Number of subjects: 19
Study 25529474 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Oasys for Presbyopia
Number of subjects: 19
Study 25529474 — intervention group
Group type: COMPARATOR
Intervention: Naked eye
Number of subjects: 19
Study 23498899 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant coffee containing 3 mg of caffeine/kg body weight
Number of subjects: 33
Study 23498899 — intervention group
Group type: EXPERIMENTAL
Intervention: Instant coffee containing 6 mg of caffeine/kg body weight
Number of subjects: 33
Study 23498899 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 33
Study 21210182 — intervention group
Group type: EXPERIMENTAL
Intervention: GDT with 2-back working memory task (high executive load)
Number of subjects: 0
Study 21210182 — intervention group
Group type: EXPERIMENTAL
Intervention: GDT with 1-back working memory task (low executive load)
Number of subjects: 0
Study 21210182 — intervention group
Group type: COMPARATOR
Intervention: GDT without secondary task
Number of subjects: 0
Study 19124484 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexpression of alpha6beta4 integrin and Net1
Number of subjects: 94
Study 19124484 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexpression of alpha6beta4 integrin and Net1 in hormone receptor-positive tumors
Number of subjects: 94
Study 19124484 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphovascular invasion
Number of subjects: 94
Study 17475318 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct mailing
Number of subjects: 70
Study 17475318 — intervention group
Group type: EXPERIMENTAL
Intervention: Newspaper advertisements
Number of subjects: 70
Study 17475318 — intervention group
Group type: EXPERIMENTAL
Intervention: Other sources (e.g., word of mouth)
Number of subjects: 70
Study 17475318 — intervention group
Group type: EXPERIMENTAL
Intervention: Posters and brochures
Number of subjects: 70
Study 15127079 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (RU-486) 600 mg/day
Number of subjects: 20
Study 15127079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11445772 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive contractions lasting 4 s
Number of subjects: 16
Study 11445772 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic contractions lasting about 1 s
Number of subjects: 16
Study 9593071 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 27
Study 9593071 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 27
Study 9593071 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 7838620 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzyl-benzoate foam
Number of subjects: 24
Study 7838620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7838620 — intervention group
Group type: COMPARATOR
Intervention: No treatment (absolute control)
Number of subjects: 24
Study 3044868 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg aspirin
Number of subjects: 120
Study 3044868 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg mefenamic acid
Number of subjects: 120
Study 3044868 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 650 mg aspirin and 250 mg mefenamic acid
Number of subjects: 120
Study 3044868 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30572524 — intervention group
Group type: EXPERIMENTAL
Intervention: TMBCZG high-dose group (3 tablets, twice per day)
Number of subjects: 160
Study 30572524 — intervention group
Group type: EXPERIMENTAL
Intervention: TMBCZG middle-dose group (2 tablets and placebo 1 tablet twice per day)
Number of subjects: 160
Study 30572524 — intervention group
Group type: EXPERIMENTAL
Intervention: TMBCZG low-dose group (1 tablet and placebo 2 tablets, twice per day)
Number of subjects: 160
Study 30572524 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (placebo 3 tablets, twice per day)
Number of subjects: 160
Study 30572524 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 160
Study 28388932 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium benzoate (1000 mg, 500 mg twice daily for 12 weeks)
Number of subjects: 160
Study 28388932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 26035291 — intervention group
Group type: EXPERIMENTAL
Intervention: o‐CEE (0.45 mg/d) plus m‐P (200 mg/d for the first 12 d of each month)
Number of subjects: 693
Study 26035291 — intervention group
Group type: EXPERIMENTAL
Intervention: t‐E2 (50 μg/d) plus m‐P (200 mg/d for the first 12 d of each month)
Number of subjects: 693
Study 26035291 — intervention group
Group type: COMPARATOR
Intervention: Placebo pills and patches
Number of subjects: 693
Study 24282343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging treatments (transarterial chemoembolization, radiofrequency ablation, surgical resection)
Number of subjects: 0
Study 24282343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging treatments
Number of subjects: 0
Study 24282343 — intervention group
Group type: EXPERIMENTAL
Intervention: Downstaging treatments
Number of subjects: 0
Study 20883846 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm Water Infusion (WWI)
Number of subjects: 230
Study 20883846 — intervention group
Group type: COMPARATOR
Intervention: Air Insufflation (AI)
Number of subjects: 230
Study 18413618 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-microL testosterone metered-dose transdermal spray
Number of subjects: 261
Study 18413618 — intervention group
Group type: EXPERIMENTAL
Intervention: 56-microL testosterone metered-dose transdermal spray
Number of subjects: 261
Study 18413618 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 90-microL testosterone metered-dose transdermal sprays
Number of subjects: 261
Study 18413618 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study 15899748 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute self-administered intervention with normative feedback and goal setting
Number of subjects: 155
Study 15899748 — intervention group
Group type: COMPARATOR
Intervention: Control condition (reading a general AIDS information pamphlet)
Number of subjects: 155
Study 12091193 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose lithium (serum level=0.4-0.6 meq/liter)
Number of subjects: 94
Study 12091193 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose lithium (serum level=0.8-1.0 meq/liter)
Number of subjects: 94
Study 10343191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate 1,200 mg (arm I)
Number of subjects: 80
Study 10343191 — intervention group
Group type: COMPARATOR
Intervention: Oral medroxyprogesterone acetate 600 mg (arm II)
Number of subjects: 80
Study 10343191 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral medroxyprogesterone acetate (both arms)
Number of subjects: 80
Study 8745317 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon‐alpha (rIFN) treatment
Number of subjects: 30
Study 8745317 — intervention group
Group type: COMPARATOR
Intervention: Untreated carriers undergoing spontaneous HBeAb seroconversion
Number of subjects: 30
Study 2028771 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate
Number of subjects: 404
Study 2028771 — intervention group
Group type: COMPARATOR
Intervention: Methylcellulose
Number of subjects: 404
Study 6119764 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (Flagyl) for 2 weeks
Number of subjects: 9
Study 6119764 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine (Salazopyrin) for 2 weeks
Number of subjects: 9
Study 30879128 — intervention group
Group type: COMPARATOR
Intervention: nPRP
Number of subjects: 30
Study 30879128 — intervention group
Group type: COMPARATOR
Intervention: nPRP + ASC
Number of subjects: 30
Study 30712963 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal chemotherapy after complete or optimal primary surgery
Number of subjects: 0
Study 30712963 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatinum at interval surgery
Number of subjects: 0
Study 30712963 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 29037633 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates sessions, twice a week for 12 weeks
Number of subjects: 32
Study 29037633 — intervention group
Group type: COMPARATOR
Intervention: Control group (static stretching)
Number of subjects: 32
Study 25802890 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel
Number of subjects: 105
Study 25802890 — intervention group
Group type: COMPARATOR
Intervention: proseal
Number of subjects: 105
Study 25802890 — intervention group
Group type: COMPARATOR
Intervention: supreme
Number of subjects: 105
Study 24025001 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of morphine (10-cc volume)
Number of subjects: 82
Study 24025001 — intervention group
Group type: COMPARATOR
Intervention: 10 cc of .5% bupivacaine
Number of subjects: 82
Study 21868190 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block (10 mL of 1% ropivacaine)
Number of subjects: 45
Study 21868190 — intervention group
Group type: COMPARATOR
Intervention: Subacromial infiltration of local anesthesia (20 mL of 1% ropivacaine)
Number of subjects: 45
Study 21868190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 19152449 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPIRI
Number of subjects: 46
Study 19152449 — intervention group
Group type: COMPARATOR
Intervention: CAPIRI-Bev
Number of subjects: 46
Study 17356255 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute aerobic exercise
Number of subjects: 69
Study 17356255 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 69
Study 17356255 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 69
Study 15482085 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement therapy (MET)
Number of subjects: 63
Study 15482085 — intervention group
Group type: COMPARATOR
Intervention: Standard-care practitioner advice
Number of subjects: 63
Study 11553192 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression symptoms in female patients with Type 2 diabetes
Number of subjects: 1611
Study 11553192 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression symptoms in male patients with Type 2 diabetes
Number of subjects: 1611
Study 11553192 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression symptoms in female patients (general)
Number of subjects: 1611
Study 11553192 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression symptoms in male patients (general)
Number of subjects: 1611
Study 10875887 — intervention group
Group type: EXPERIMENTAL
Intervention: rHCG (250 microg)
Number of subjects: 190
Study 10875887 — intervention group
Group type: COMPARATOR
Intervention: uHCG (5000 IU)
Number of subjects: 190
Study 9286801 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact Ho:YAG LTK (1 or 2 symmetrical octagonal rings of 8 spots/ring, 10 pulses of laser light at 5 Hz, variable pulse energy 208‐242 mJ)
Number of subjects: 28
Study 9286801 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact Ho:YAG LTK (1 ring treatment)
Number of subjects: 28
Study 9286801 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact Ho:YAG LTK (2 ring treatment)
Number of subjects: 28
Study 9286801 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncontact Ho:YAG LTK
Number of subjects: 28
Study 1493083 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 35
Study 1493083 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 3033444 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated oestrogens (CE) 0.625 mg/day for 21 days + norethisterone (NET) 5 mg/day from day 12 to day 21
Number of subjects: 113
Study 3033444 — intervention group
Group type: EXPERIMENTAL
Intervention: CE + cyproterone acetate (CPA) 12.5 mg/day from day 1 to day 10
Number of subjects: 113
Study 3033444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol valerate (EV) 2 mg/day for 21 days + NET
Number of subjects: 113
Study 3033444 — intervention group
Group type: EXPERIMENTAL
Intervention: EV + CPA
Number of subjects: 113
Study 3033444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestriol (E3) 2‐4 mg/day
Number of subjects: 113
Study 3033444 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (ORG OD14) 2.5 mg/day
Number of subjects: 113
Study 3033444 — intervention group
Group type: COMPARATOR
Intervention: Placebo, one tablet/day
Number of subjects: 113
Study 29340676 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (n=121)
Number of subjects: 240
Study 29340676 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass (n=119)
Number of subjects: 240
Study 26803560 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading group
Number of subjects: 19
Study 26803560 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading group
Number of subjects: 19
Study 24965272 — intervention group
Group type: EXPERIMENTAL
Intervention: SonixGPS-guided PCNL
Number of subjects: 88
Study 24965272 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrasound-guided PCNL
Number of subjects: 88
Study 23113955 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine practice assessment and feedback
Number of subjects: 5227
Study 23113955 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment-only without feedback
Number of subjects: 5227
Study 23113955 — intervention group
Group type: COMPARATOR
Intervention: Neither assessment nor feedback
Number of subjects: 5227
Study 23113955 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback intervention for risky drinkers
Number of subjects: 5227
Study 20402565 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 613
Study 20402565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 613
Study 18580254 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane transplantation (AMT)
Number of subjects: 12
Study 16098015 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended genetic counselling (two sessions of education and reflection held 1 month apart)
Number of subjects: 26
Study 16098015 — intervention group
Group type: COMPARATOR
Intervention: Shortened genetic counselling (a single educational session)
Number of subjects: 26
Study 12619423 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin
Number of subjects: 62
Study 12619423 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine pomade
Number of subjects: 62
Study 10797866 — intervention group
Group type: EXPERIMENTAL
Intervention: SPE‐712‐1 oral suspension 300 mg/15 mL
Number of subjects: 24
Study 10797866 — intervention group
Group type: COMPARATOR
Intervention: Rotram tablets 300 mg
Number of subjects: 24
Study 7720912 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized DHEA (50 mg/d)
Number of subjects: 11
Study 7720912 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 2116441 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion started 1 min after TRH (Group A)
Number of subjects: 18
Study 2116441 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion started 10 min after TRH (Group B)
Number of subjects: 18
Study 2116441 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion started 20 min after TRH (Group C)
Number of subjects: 18
Study 2116441 — intervention group
Group type: COMPARATOR
Intervention: Control study (no calcium infusion)
Number of subjects: 18
Study 31938840 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 cc autologous muscle-derived cell (AMDC) injections
Number of subjects: 58
Study 31938840 — intervention group
Group type: COMPARATOR
Intervention: 4 cc placebo solution injections
Number of subjects: 58
Study 30204685 — intervention group
Group type: EXPERIMENTAL
Intervention: Mozart's Symphony No. 40
Number of subjects: 208
Study 30204685 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 208
Study 26645209 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40-80 mg/d, flexibly dosed)
Number of subjects: 285
Study 26645209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 25091659 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab (in combination with trastuzumab and docetaxel)
Number of subjects: 0
Study 25091659 — intervention group
Group type: COMPARATOR
Intervention: Control (trastuzumab plus docetaxel)
Number of subjects: 0
Study 22069246 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant inflammatory bowel disease (IBD)
Number of subjects: 82
Study 22069246 — intervention group
Group type: COMPARATOR
Intervention: No concomitant inflammatory bowel disease (Control group)
Number of subjects: 82
Study 20182880 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-staged ORIF
Number of subjects: 56
Study 20182880 — intervention group
Group type: COMPARATOR
Intervention: Limited internal fixation with external fixator (LIFEF)
Number of subjects: 56
Study 18801382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound intensity change
Number of subjects: 0
Study 18801382 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 16158743 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanefron H (KH) with phosphomycin (2 pellets 3 times a day for 30 days)
Number of subjects: 48
Study 16158743 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanefron H (KH) after initial anti-inflammatory treatment
Number of subjects: 48
Study 16158743 — intervention group
Group type: COMPARATOR
Intervention: Control group (spasmolytic and anti-inflammatory therapy)
Number of subjects: 48
Study 12665729 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted instructional (CAI) game focusing on reducing environmental irritants/allergens and correct use of prescribed medications for 12 weeks
Number of subjects: 101
Study 12665729 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 101
Study 10757465 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril (10 mg) administered in the morning (07:00)
Number of subjects: 20
Study 10757465 — intervention group
Group type: EXPERIMENTAL
Intervention: Imidapril (10 mg) administered in the evening (18:00)
Number of subjects: 20
Study 8843225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent recombinant baculovirus influenza A vaccine (rHA0)
Number of subjects: 0
Study 8843225 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent recombinant baculovirus influenza A vaccine (rHA0)
Number of subjects: 0
Study 8843225 — intervention group
Group type: COMPARATOR
Intervention: Standard trivalent inactivated vaccine (TIV)
Number of subjects: 0
Study 8843225 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of A/Texas rHA0 (15 micrograms)
Number of subjects: 0
Study 8843225 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of A/Texas rHA0 (45 micrograms)
Number of subjects: 0
Study 8843225 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing doses of A/Texas rHA0 (135 micrograms)
Number of subjects: 0
Study 8843225 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent HA
Number of subjects: 0
Study 1378478 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical retinoic acid (RA) treatment
Number of subjects: 5
Study 1378478 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 5